Medicare Formulary Coverage for Top-selling Biologics

Overview

Journal Nat Biotechnol

Specialty Biotechnology

Date 2009 Dec 17

PMID 20010576

Citations 6

Authors

Su-Ying Liang

Jennifer S Haas

Kathryn A Phillips

Affiliations

Soon will be listed here.

Citing Articles

The Inclusion of Economic Endpoints as Outcomes in Clinical Trials Reported to ClinicalTrials.gov.

Mitchell J, Patterson J J Manag Care Spec Pharm. 2020; 26(4):386-393.

PMID: 32223593 PMC: 10391117. DOI: 10.18553/jmcp.2020.26.4.386.

Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval.

Shaw D, Dhruva S, Ross J J Manag Care Spec Pharm. 2018; 24(12):1230-1238.

PMID: 30479199 PMC: 10397592. DOI: 10.18553/jmcp.2018.24.12.1230.

Improving Access to Cancer Treatments: The Role of Biosimilars.

Chopra R, Lopes G J Glob Oncol. 2017; 3(5):596-610.

PMID: 29094099 PMC: 5646904. DOI: 10.1200/JGO.2016.008607.

Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.

Yazdany J, Dudley R, Chen R, Lin G, Tseng C Arthritis Rheumatol. 2015; 67(6):1474-80.

PMID: 25900105 PMC: 4464809. DOI: 10.1002/art.39079.

A review of approaches for the management of specialty pharmaceuticals in the United States.

Patel B, Audet P Pharmacoeconomics. 2014; 32(11):1105-14.

PMID: 25118989 PMC: 4209107. DOI: 10.1007/s40273-014-0196-0.

References

Tseng C, Mangione C, Brook R, Keeler E, Dudley R . Identifying widely covered drugs and drug coverage variation among Medicare part D formularies. JAMA. 2007; 297(23):2596-602. DOI: 10.1001/jama.297.23.2596. View

Stern D, Reissman D . Specialty pharmacy cost management strategies of private health care payers. J Manag Care Pharm. 2007; 12(9):736-44. PMC: 10438281. DOI: 10.18553/jmcp.2006.12.9.736. View

Daniel Mullins C, Lavallee D, Pradel F, DeVries A, Caputo N . Health plans' strategies for managing outpatient specialty pharmaceuticals. Health Aff (Millwood). 2006; 25(5):1332-9. DOI: 10.1377/hlthaff.25.5.1332. View

Bowman J, Rousseau A, Silk D, Harrison C . Access to cancer drugs in Medicare Part D: formulary placement and beneficiary cost sharing in 2006. Health Aff (Millwood). 2006; 25(5):1240-8. DOI: 10.1377/hlthaff.25.5.1240. View

Huskamp H, Stevenson D, Donohue J, Newhouse J, Keating N . Coverage and prior authorization of psychotropic drugs under Medicare Part D. Psychiatr Serv. 2007; 58(3):308-10. DOI: 10.1176/ps.2007.58.3.308. View